Supplements

Duloxetine treatment improves sleep quality and reduces serum pro-inflammatory cytokine levels in patients with major depressive disorder

After 4 weeks of duloxetine treatment (40-60 mg/day), patients with MDD showed significant improvements in sleep parameters including increased total sleep time (TST) and sleep efficiency (SE), and decreased wake after sleep onset (WASO). Serum levels of pro-inflammatory cytokines IL-1β, IL-8, IL-12, and IFN-γ were significantly reduced. Baseline correlations and concurrent changes in sleep and cytokine levels suggest a link between sleep improvement and inflammatory regulation during duloxetine intervention.

Last updated: Jul 8, 2026•0 RCTs•📖 Read as article →

Evidence Score

Evidence Score34/100
Human RCT☆☆☆☆☆
Meta-analysis☆☆☆☆☆
Mechanism★★★★★
Safety★★★★☆
Confidencelow

Study Evidence

Study 1. Association between changes in sleep quality and serum pro-inflammatory cytokine levels in patients with major depressive disorder following duloxetine treatment.

observational

Xu Y, Gao W, Shan F, Xia Q, Liang J · Annals of general psychiatry (2026)

Participants: N/A
Duration: 4 weeks
Intervention: Duloxetine at a daily dose of 40-60 mg for 4 consecutive weeks
Outcome: Objective sleep parameters (TST, SE, WASO, REM latency) measured by polysomnography; serum levels of IL-1β, IL-6, IL-8, IL-12, TNF-α, and IFN-γ
Effect Size: N/A (t-values reported: TST t=-6.614, SE t=-6.631, WASO t=6.331, IL-1β t=4.759, IL-8 t=6.327, IL-12 t=6.194, IFN-γ t=8.713; all P<0.001)
Population: 74 patients with major depressive disorder (DSM-5 criteria, baseline 24-item HDRS score ≥20, no prior antidepressant or anti-inflammatory drug use within 3 months)

Result:

PubMed: 42366392DOI: 10.1186/s12991-026-00689-8

Mechanism Graph

Duloxetine inhibits serotonin and norepinephrine reuptake
↓
Reduces peripheral pro-inflammatory cytokine levels (IL-1β, IL-8, IL-12, IFN-γ)
↓
Improves objective sleep parameters (increases TST and SE, decreases WASO)
↓
Concurrent changes in sleep and cytokines suggest a potential link between sleep improvement and inflammatory regulation

Limitations

  • ⚠Open-label design without a placebo control group limits causal inference
  • ⚠Short treatment duration (4 weeks) may not capture long-term effects
  • ⚠Correlational analyses do not establish causality between sleep improvement and cytokine changes

Frequently Asked Questions

What sleep parameters improved with duloxetine treatment?▼

Total sleep time (TST) and sleep efficiency (SE) significantly increased, while wake after sleep onset (WASO) significantly decreased after 4 weeks of duloxetine treatment.

Which pro-inflammatory cytokines were reduced after duloxetine treatment?▼

Serum levels of IL-1β, IL-8, IL-12, and IFN-γ were significantly reduced following 4 weeks of duloxetine treatment.

Was there a correlation between sleep improvement and cytokine changes?▼

Yes, the change in TST was negatively correlated with the change in IL-12 levels, and the change in sleep efficiency was negatively correlated with changes in IL-8 and IL-12 levels.

What was the study population?▼

The study included 74 patients with major depressive disorder diagnosed by DSM-5 criteria, with a baseline 24-item Hamilton Depression Rating Scale score ≥20, and no prior antidepressant or anti-inflammatory drug use within 3 months.

Products

Affiliate links coming soon. We only recommend products that match the doses and forms used in the cited research.

References

  1. 1.Xu Y, Gao W, Shan F, Xia Q, Liang J. "Association between changes in sleep quality and serum pro-inflammatory cytokine levels in patients with major depressive disorder following duloxetine treatment.." Annals of general psychiatry, 2026. PMID: 42366392 DOI: 10.1186/s12991-026-00689-8
Disclaimer: This content is for educational purposes only and is not medical advice. Evidence scores reflect the quality and quantity of available research, not clinical recommendations. Always consult a healthcare professional before starting any supplement or intervention.